Pyrrolopyrazine derivatives

A compound of the formula:

• ##STR19## wherein one of R.sup.1 and R.sup.2 is aryl and the other is hydrogen, lower alkyl or aryl, or R.sup.1 and R.sup.2 together with the two carbon atoms denoted by .alpha. and .beta., is the following group A:
• ##STR20## wherein:
• X is halogen;
• R.sup.32 is lower alkyl;
• R.sup.5 is hydrogen or lower alkyl;
• R.sup.6 is hydrogen or lower alkyl;
• R.sup.7 is hydrogen, halogen, lower alkyl, unsubstituted lower alkoxy, C.sub.3-6 -cycloalkyl, C.sub.4-6 -cycloalkenyl, C.sub.3-6 -cycloalkyloxy, hydroxy, trifluoromethanesulphonyloxy, unsubstituted benzyloxycarbonyloxy, substituted benzyloxycarbonyl wherein a hydrogen atom on the phenyl ring is replaced by a nitro group, or substituted lower alkoxy wherein at least one hydrogen atom on the alkyl group is replaced by (i) oxo, (ii) hydroxy, (iii) a 5- or 6-membered unsubstituted saturated heterocycle ring having one nitrogen atom with the remaining ring atoms being carbon, the ring being attached via the nitrogen atom, or (iv) a 5- or 6-membered unsubstituted saturated heterocycle ring having one nitrogen atom and one oxygen atom with the remaining ring atoms being carbon, the ring being attached via the nitrogen atom;
• and the ring carbon atom substituted by R.sup.6 can be saturated or unsaturated.

A medicament comprising a compound having the formula:

• ##STR21## wherein one of R.sup.1 and R.sup.2 is aryl and the other is hydrogen, lower alkyl or aryl, or R.sup.1 and R.sup.2 together with the two carbon atoms denoted by .alpha. and .beta., is the following group A:
• ##STR22## wherein:
• R.sup.3 is hydrogen or lower alkyl and R.sup.4 is hydrogen or
• R.sup.3 and R.sup.4 together are an additional C--N bond;
• R.sup.5 is hydrogen or lower alkyl;
• R.sup.6 is hydrogen or lower alkyl;
• R.sup.7 is hydrogen, halogen, lower alkyl, unsubstituted lower alkoxy, C.sub.3-6 -cycloalkyl, C.sub.4-6 -cycloalkenyl, C.sub.3-6 -cycloalkyloxy, hydroxy, trifluoromethanesulphonyloxy, unsubstituted benzyloxycarbonyloxy, benzyloxyxcarbonyloxy substituted on its phenyl ring with nitro, or substituted lower alkoxy wherein at least one hydrogen atom on the alkyl group is replaced by (i) oxo, (ii) hydroxy, (iii) a 5- or 6-membered unsubstituted saturated heterocycle ring having one nitrogen atom with the remaining ring atoms being carbon, the ring being attached via the nitrogen atom, or (iv) a 5- or 6-membered unsubstituted saturated heterocycle ring having one nitrogen atom and one oxygen atom with the remaining ring atoms being carbon, the ring being attached via the nitrogen atom;
• and
• the ring carbon atom substituted by R.sup.6 can be saturated or unsaturated;
• and pharmaceutically acceptable acid addition salts of the compounds of formula I;
• and a therapeutically inert carrier material.